Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,147
archived clinical trials in
Asthma

Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
mi
from
Spartanburg, SC
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
mi
from
Spartanburg, SC
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
mi
from
Rapid CIty, SD
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
mi
from
Rapid CIty, SD
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
mi
from
Tullahoma, TN
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
mi
from
Tullahoma, TN
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
mi
from
El Paso, TX
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
mi
from
El Paso, TX
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
mi
from
Houston, TX
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
mi
from
Houston, TX
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
mi
from
Plano, TX
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
mi
from
Plano, TX
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
mi
from
San Antonio, TX
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated:  2/17/2016
Pearl Therapeutics Study Site
mi
from
Everett, WA
Chronic Dosing, Cross-Over Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma
Status: Enrolling
Updated: 2/17/2016
Pearl Therapeutics Study Site
mi
from
Everett, WA
Click here to add this to my saved trials
Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults
Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults (A Randomized, Evaluator-Blind, Single-Dose, Two Arm, Crossover, PK Study in Healthy Volunteers)
Status: Enrolling
Updated:  2/18/2016
West Coast Clinical Trials, LLC
mi
from
Cypress, CA
Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults
Assessment and Evaluation of Pharmacokinetic Profile of E004 in Healthy Adults (A Randomized, Evaluator-Blind, Single-Dose, Two Arm, Crossover, PK Study in Healthy Volunteers)
Status: Enrolling
Updated: 2/18/2016
West Coast Clinical Trials, LLC
mi
from
Cypress, CA
Click here to add this to my saved trials
Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS
CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS, A Randomized, Evaluator-Blind, Single-Dose, Three Arm, Crossover,PK Study in Healthy Volunteers
Status: Enrolling
Updated:  2/18/2016
Amphastar Study Site 1
mi
from
Cypress, CA
Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS
CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS, A Randomized, Evaluator-Blind, Single-Dose, Three Arm, Crossover,PK Study in Healthy Volunteers
Status: Enrolling
Updated: 2/18/2016
Amphastar Study Site 1
mi
from
Cypress, CA
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Hamzavi Dermatology/Dermatology Specialists of Canton
mi
from
Canton, MI
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Hamzavi Dermatology/Dermatology Specialists of Canton
mi
from
Canton, MI
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Hamzavi Dermatology
mi
from
Fort Gratiot, MI
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Hamzavi Dermatology
mi
from
Fort Gratiot, MI
Click here to add this to my saved trials
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated:  2/23/2016
Lynderm Research
mi
from
Markham,
Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Randomized, Multicentric, Controlled Study on the Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis
Status: Enrolling
Updated: 2/23/2016
Lynderm Research
mi
from
Markham,
Click here to add this to my saved trials
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Status: Enrolling
Updated:  2/24/2016
William S. Middleton Memorial Veterans Hospital, Madison, WI
mi
from
Madison, WI
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Inhaled Fluticasone Effects on Upper Airway Patency in Obstructive Lung Disease
Status: Enrolling
Updated: 2/24/2016
William S. Middleton Memorial Veterans Hospital, Madison, WI
mi
from
Madison, WI
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Baylor College of Medicine
mi
from
Houston, TX
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Hofstra North Shore-LIJ School of Medicine
mi
from
New Hyde Park, NY
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Hofstra North Shore-LIJ School of Medicine
mi
from
New Hyde Park, NY
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Louisiana State University Health Sciences Center, The Ernest N. Morial Asthma, Allergy and Respiratory Disease Center
mi
from
New Orleans, LA
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Louisiana State University Health Sciences Center, The Ernest N. Morial Asthma, Allergy and Respiratory Disease Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Maria Fareri Children's Hospital at Westchester Medical Center and New York Medical College
mi
from
Valhalla, NY
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Maria Fareri Children's Hospital at Westchester Medical Center and New York Medical College
mi
from
Valhalla, NY
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
National Jewish Health
mi
from
Denver, CO
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Nemours Children's Clinic
mi
from
Jacksonville, FL
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Nemours Children's Clinic
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
New York University School of Medicine
mi
from
New York, NY
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Northern New England Consortium
mi
from
Colchester, VT
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Northern New England Consortium
mi
from
Colchester, VT
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
St. Vincent Healthcare
mi
from
Indianapolis, IN
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
St. Vincent Healthcare
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
St. Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
St. Vincent Hospital and Health Care Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Illinois Consortium
mi
from
Chicago, IL
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Illinois Consortium
mi
from
Chicago, IL
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
University of Arizona, Arizona Respiratory Center
mi
from
Tucson, AZ
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
University of Arizona, Arizona Respiratory Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
University of Miami/University of South Florida
mi
from
Tampa, FL
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
University of Miami/University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
University of Missouri, Kansas City School of Medicine
mi
from
Kansas City, MO
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
University of Missouri, Kansas City School of Medicine
mi
from
Kansas City, MO
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
University of Virginia
mi
from
Charlottesville, VA
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Washington University/St. Louis University
mi
from
St. Louis, MO
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Washington University/St. Louis University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
University of California, San Diego
mi
from
San Diego, CA
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
University of California, San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated:  2/26/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Long-acting Beta Agonist Step Down Study
Long-acting Beta Agonist Step Down Study
Status: Enrolling
Updated: 2/26/2016
Ohio State University Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Scottsdale, AZ
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Encinitas, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Encinitas, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Huntington Beach, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative site
mi
from
Los Angeles, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigational Site
mi
from
Orange, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigational Site
mi
from
Orange, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Riverside, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Riverside, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
San Diego, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
San Diego, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
San Jose, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
San Jose, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
San Mateo, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
San Mateo, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Stockton, CA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Stockton, CA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis
mi
from
Denver, CO
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis
mi
from
Denver, CO
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Sarasota, FL
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Sarasota, FL
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Savannah, GA
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Savannah, GA
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
River Forest, IL
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
River Forest, IL
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Bangor, ME
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Bangor, ME
Click here to add this to my saved trials
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated:  3/3/2016
Novartis Investigative Site
mi
from
Wheaton, MD
Dose Finding Study for QAW039 in Asthma
A Randomized, Placebo-controlled, Dose-ranging, Multi-centre Trial of QAW039 (1-450 mg p.o.), to Investigate the Effect on FEV1 and ACQ in Patients With Moderate-to-severe, Persistent, Allergic Asthma, Inadequately Controlled With ICS Therapy.
Status: Enrolling
Updated: 3/3/2016
Novartis Investigative Site
mi
from
Wheaton, MD
Click here to add this to my saved trials